Koss sales and profits improve as exports to europe strengthen - Pneumatic And Hydraulic Actuators

Koss Corporation(NASDAQ: KOSS), the U.S. based high-fidelity headphone company, hasreported its results for the quarter ended March 31, 2012. Salesfor the third quarter were $8,232,526 compared to $8,419,663 forthe same three month period one year ago, a 2% decrease. Net incomeincreased to $896,715, compared to $640,962 for the third quarterlast year. Diluted income per common share was $0.12 compared with$0.09 one year ago.

Sales for the nine months ended March 31, 2012 trended down by 14%to $26,978,082 compared with $31,252,603 for the same nine monthperiod a year ago. Nine month net income declined to $2,008,524compared to $2,585,934 for the same nine months last year. Dilutedincome per common share was $0.27 compared with $0.35 one year ago. "Europe rebounded in the quarter to show a small increase over lastyear, but it is still behind last year through the nine months.

Itwas great to see the increase in activity and we hope it will carryinto our fourth quarter," Michael J. Koss, President and CEO saidhere today. "We continued to see lower than expected orders fromseveral major U.S. retailers which contributed to the small declinein this quarter compared to last year. API Check Valves

The additions of newcustomers and products has helped to offset the impact from theseU.S. retailers." Koss went on to note that the Company has continued to benegatively impacted by higher costs from suppliers in China but hasbeen able to partially offset the impact through alternatesuppliers and pricing. These costs have hurt margins this year. "We saw increased activity late in the quarter," Koss said. Pneumatic And Hydraulic Actuators

"Rightnow we have a lot of new and exciting products hitting the market.The most exciting of these is Striva, which was announced earlierthis week. The two Striva products are the world's first Wi-Fiheadphones to receive music directly from the internet. Therevolution is in the air." The Company will pay a dividend of $0.06 cents per share on July16, 2012, to shareholders of record on June 29, 2012. Koss Corporation markets a complete line of high-fidelityheadphones, speaker-phones, computer headsets, telecommunicationsheadsets, active noise canceling headphones, wireless headphones,and compact disc recordings of American Symphony Orchestras on theKoss Classics label. This press release contains forward-looking statements. China Pneumatic Gate Valves

Thesestatements relate to future events or our future financialperformance. In some cases, you can identify forward-lookingstatements by terminology such as "may," "will," "should,""forecasts," "expects," "plans," "anticipates," "believes,""estimates," "predicts," "potential," or "continue" or the negativeof such terms and other comparable terminology. These statementsare only predictions. Actual events or results may differmaterially.

In evaluating forward-looking statements, you shouldspecifically consider various factors that may cause actual resultsto vary from those contained in the forward-looking statements,such as general economic conditions, in particular, consumer demandfor the Company's and its customers' products, competitive andtechnological developments, foreign currency fluctuations, andcosts of operations. Shareholders, potential investors and otherreaders are urged to consider these factors carefully in evaluatingthe forward-looking statements and are cautioned not to place unduereliance on such forward-looking statements. The forward-lookingstatements made herein are only made as of the date of this pressrelease and the Company undertakes no obligation to publicly updatesuch forward-looking statements to reflect subsequent events orcircumstances. In addition, such uncertainties and otheroperational matters are discussed further in the Company'squarterly and annual filings with the Securities and ExchangeCommission.

Nanostructure promotes growth of new blood vessels, mimics naturalprotein - China taxi roof lights

Tissue deprived of oxygen (ischemia) is a serious health conditionthat can lead to damaged heart tissue following a heart attack and, in the case of peripheral arterial disease in limbs, amputation, particularly in diabetic patients. Northwestern University researchers have developed a novelnanostructure that promotes the growth of new blood vessels andshows promise as a therapy for conditions where increased bloodflow is needed to supply oxygen to tissue. "An important goal in regenerative medicine is the ability to growblood vessels on demand," said Samuel I. Stupp, Board of TrusteesProfessor of Chemistry, Materials Science and Engineering, andMedicine. "Enhancing blood flow at a given site is important whereblood vessels are constricted or obstructed as well as in organtransplantation where blood is needed to feed the cells properly." Stupp led the study that will be published the week of Aug.

1 bythe Proceedings of the National Academy of Sciences (PNAS). Stupp and his team designed an artificial structure that, like thenatural protein it mimics, can trigger a cascade of complex eventsthat promote the growth of new blood vessels. The protein thenanostructure mimics is called vascular endothelial growth factor,or VEGF. The nanostructure, however, exhibits important advantages overVEGF: it remains in the tissue where it is needed for a longerperiod of time; it is easily injected as a liquid to the tissue;and, relative to the protein, it is inexpensive to produce. (VEGFwas tested in human clinical trials but without good results,possibly due to it remaining in the tissue for only a few hours.) "One of the major challenges in the field of ischemic tissue repairis sustained delivery of therapeutic agents to target tissue," saidDouglas W.

Losordo, M.D., a co-author of the paper and director ofNorthwestern's Feinberg Cardiovascular Research Institute. "NativeVEGF has a very short tissue half-life, limiting its potency andrequiring repeat dosing. By virtue of its engineering, thisnanomaterial mimics VEGF but is capable of much longer life in thetissue, greatly enhancing its potency." Losordo also is the Eileen M. Foell Professor of Heart Research atNorthwestern's Feinberg School of Medicine and director of theProgram in Cardiovascular Regenerative Medicine at NorthwesternMemorial Hospital. yellow fog light bulbs

"We approached this as an engineering problem," said first authorMatthew Webber, a doctoral student in Stupp's research group at theInstitute for BioNanotechnology in Medicine (IBNAM). "To be able todesign and create a small molecule that can assemble intonanostructures that function therapeutically is rewarding." Stupp and his team created a nanostructure in the form of a fiberthat displays on its surface a high density of peptides(potentially hundreds of thousands) per fiber. The peptides mimicthe biological effect of VEGF, initiating the signaling process incells that leads to blood vessel growth. The extremely large number of active peptides results in a verypotent therapeutic, and the size and stability of the nanofiberensure the structure is retained longer in the tissue afterinjection. After developing the nanostructure, Stupp and Webber teamed up withLosordo to test the nanostructures in vivo. China taxi roof lights

The researchers used an animal model of peripheral arterial diseaseand demonstrated the effectiveness of the nanofiber in treating thecondition. In animals whose limbs were restricted to only 5 to 10percent of normal blood flow, treatment with the nanofiber resultedin blood flow being restored to 75 to 80 percent of normal levels. Treatment with the peptide alone did not produce the sametherapeutic effect; the nanostructure was needed to display thepeptides to produce results. "Using simple chemistry, we have produced an artificial structureby design that can trigger complex events," said Stupp, who isdirector of IBNAM. motorcycle fog lights

"Our nanostructure shows the promise of ageneral approach to mimicking proteins for broader use in medicineand biotechnology." The researchers next plan to investigate the protein mimic in aheart attack animal model. The paper is titled "Supramolecular Nanostructures that Mimic VEGFas a Strategy for Ischemic Tissue Repair." In addition to Stupp,Losordo and Webber, other authors of the paper are J rn Tongers,Christina Newcomb and Katja-Theres Marquardt, of NorthwesternUniversity; and Johan Bauersachs, of Hannover Medical School,Hannover, Germany. Additional References Citations.

Introducing the new triple analyser from cambridge sensotec - China High Pressure Needle Valve

Cambridge Sensotec is proud to release our latest multigas product,the Rapidox 3100EAB. The Rapidox 3100EAB is a multi-gas analyserfor measuring O 2 , CO 2 and CO simultaneously. The analyser allows accurate analysis overthe oxygen range 0 to 100% O 2 with a resolution of 0.01%, CO 2 and CO ranges are selectable at time of purchase. The Rapidox3100EAB analyser provides continuous on-line gas analysis, with atypical response time of less than 20 seconds for a 90% step changein O 2 compositions and approximately 30 seconds for a 90% step change inCO 2 and CO compositions. The analyser contains a powerful Nitto motor-driven diaphragmvacuum pump which draws a gas sample at a rate that can be set bythe user.

The flow of gas can be adjusted using the flowgauge/High Pressure Needle Valve on the front panel of the analyser. Typical flowrate is 1 litre per minute. Alternatively the pump can beindependently switched off and operated under flowing gasconditions. An internal pressure sensor compensates for smallchanges in gas pressure to maintain the accuracy of readings.

The oxygen sensor is a Yuasa electrochemical O 2 sensor, which has a five year life expectancy and can be used in awide range of gases such as nitrogen, argon, helium and carbondioxide. The sensor is not affected by the presence ofhydrocarbons. The CO 2 and CO sensors are based on infra-red cell technology which givesextremely stable and accurate readings over a period of many years.The cells are supplied fully calibrated. The analyser is packedwith features including programmable alarm circuits, programmableanalogue outputs, RS232 communications and complete communications/ data logging software.

The Rapidox 3100EAB is also easilycalibrated with user selectable gases.
Plug Valve Lubricated is a suitable choice for enterprises that want to do business online, we provides low price and fine commodities such as China High Pressure Needle Valve, and many other products, just visit it !

High dietary fat, cholesterol linked to increase risk of prostatecancer - Gantry Crane Manufacturer

Elevated fat and cholesterol levels found in a typical American-style diet plays an importantrole in the growth and spread of prostate cancer , say researchers at Thomas Jefferson University's Kimmel CancerCenter. Their study, the first to show such an association, is published inthe December issue of The American Journal of Pathology. Itdemonstrates how mice eating a Western diet, and predisposed todevelop prostate cancer, can develop larger tumors that are fastergrowing and metastasize more easily to the lungs, compared toanimals eating a control diet. In this study, a research team led by Philippe G.

Frank, Ph.D.,assistant professor in the Department of Stem Cell Biology andRegenerative Medicine at Jefferson, tried to understand whyprostate cancer incidence is low in Asian countries, butsignificantly increases in Asian men who move to the United States."Our hypothesis is that environmental factors, most likely presentin the diet, may act as late stage promoters, responsible for thetransformation of a prostate tumor from an early stage form into amore aggressive and clinically-apparent form," says Dr. Frank. Dietary fat and cholesterol have been shown to be risk factors inthe development and progression of other tumor types, butdiet-based studies in prostate cancer patients have reachedcontradictory conclusions, Dr. Frank says. For this reason, he andhis colleagues turned to the TRAMP transgenic mouse model todetermine the role of dietary fat and cholesterol.

This mouse modelis believed to closely parallel the pathogenesis of human prostatecancer. TRAMP mice were placed on a diet that contained 21.2 percent fatand 0.2 percent cholesterol, reflective of a typical Western diet.A control group of TRAMP mice was fed a normal chow that had 4.5percent fat and negligible amounts of cholesterol. They found that the Western diet accelerated prostate tumordevelopment and progression. These tumors also produced increasedlevels of receptors that bind to lipoproteins carriers ofcholesterol, and they were more aggressive. The researchers furtherdiscovered that the TRAMP mice fed a Western diet appeared toexperience greater incidence of cancer metastasis to the lungs, compared to the control group. Launching Gantry Crane

The research team also noted that TRAMP mice fed the high fat/highcholesterol chow had less cholesterol in their blood compared tocontrol mice fed the same diet. "This likely reflects the fact thattheir tumors depend on cholesterol to grow," explains Dr. Frank."This study suggests that monitoring cholesterol levels in men atrisk, diagnosed, or treated for prostate cancer may help limitcancer growth or even recurrence." Dr. Frank says the evidence involving cholesterol is strong - afinding he believes makes sense physiologically. Gantry Crane Manufacturer

"Cells needcholesterol to produce androgen hormones, and androgen hormonespromote prostate cancer growth," he explains. "Perhaps moreimportantly, we also believe that tumors feed on cholesterol, andthe more blood cholesterol is accessible, the more is available fortumor growth. "Although this is a mouse study, numerous studies have shown thehealth benefits of controlling blood cholesterol levels and fatintake. This research suggests the same advice may offer somebenefit for men at risk of developing prostate cancer or evendiagnosed with prostate cancer," says Dr. Frank. Manual Chain Hoist Manufacturer

He adds statins that lower cellular cholesterol production may beone way to reduce prostate cancer progression - although that hasyet to be demonstrated. Monitoring blood cholesterol levels ofprostate cancer patients may also provide important informationabout cancer progression. "For example, tests showing a sudden dropin blood cholesterol is often indicative of the development oftumors," Dr. Frank adds.

Dr. Frank receives funding from the Jane Barsumian/Mary Lyons Trustand the Susan G. Komen Foundation; the first author, GemmaLlaverias Ph.D., was supported by the Spanish Ministry of Scienceand Innovation. The other study co-authors are Christiane Danilo,M.S., Yu Wang, M.S., Agnes Witkiewicz, M.D., Kristin Daumer, M.S.,and Michael Lisanti, M.D., Ph.D. All researchers are from Thomas Jefferson University, areaffiliated with the Kimmel Cancer Center, and declare no conflictsof interest.

Source: Thomas Jefferson University Additional References Citations.

Men’s breast cancer often more deadly, study suggests - yellow fog light bulbs Manufacturer

Males typically older at diagnosis, often have larger tumors,experts find. By Kathleen Doheny HealthDay Reporter FRIDAY, May 4 (HealthDay News) -- Breast cancer in men is much lesscommon than it is in women, but it may be more deadly, new researchsuggests. "Men with breast cancer don't do as well as women with breastcancer, and there are opportunities to improve that," said studyauthor Dr. Jon Greif, a breast surgeon in San Francisco.

"They wereless likely to get the standard treatments that women get." Survival rates for men with breast cancer, overall, are lower thanthose for women, at least when it is diagnosed in the early stages,Greif found. The cancers differ in other respects too. Greif was scheduled to present his findings Friday at the AmericanSociety of Breast Surgeons annual meeting in Phoenix. Greif and his team warn, however, that some of the differences theyfound may not bear out in clinical practice. A big limitation to the research: The database they drew from keepstrack of which breast cancer patients die, but not what they diedfrom.

So it is impossible to tell if they died from their cancer orsomething else, he explained. Although many men may not be aware that they can get breast cancer,nearly 2,200 new cases of male breast cancer are expected thisyear, according to the American Cancer Society. The societyestimates 410 men will die of breast cancer in 2012 in the UnitedStates. Greif compared about 13,000 men with breast cancer, identified fromthe National Cancer Data Base, to more than 1.4 million women withbreast cancer. fog lights bulbs

The data covered 1998 to 2007. The investigators evaluated cancer characteristics and survivalrates, taking into account age, ethnicity and other factors. Men with breast cancer were more likely to be black than women withbreast cancer (11.7 percent versus 9.9 percent) and less likely tobe Hispanic (3.6 percent versus 4.5 percent), the researchersfound. In addition, men were older at diagnosis -- 63, on average,compared to 59 for women. yellow fog light bulbs Manufacturer

Men's tumors were larger when diagnosed; they were more likely tohave later-stage tumors, involvement of lymph nodes, spreading toother parts of the body and other differences. Men with breast cancer were less likely to get a partial mastectomyand to receive radiation, the study found. Greif also found that women's overall five-year survival rate was83 percent, but men's was 74 percent. That was looking at allbreast cancers, whatever the stage. China auto license plate frame

When Greif's team looked at survival stage by stage, women withearly stage cancer had better survival rates than men with earlystage disease. The gap closed when men and women had more advanceddisease. "Women are encouraged to get breast exams [and] mammograms," Greifsaid. That is why their cancers are often diagnosed earlier, whenthe tumors are smaller, he said. More awareness of male breastcancer is crucial.

The study is valuable in pointing out gender differences, even withits limitations, said Dr. Susan Boolbol, chief of the division ofbreast surgery at Beth Israel Medical Center in New York City. "Over the years, it was thought that, stage for stage, women andmen had equal outcomes," Boolbol said. The new research findsotherwise, and includes larger numbers of men with breast cancerthan many previous studies did, she noted. Lack of information on cause of death is a major limitation of thefinding, she said.

Even so, "this is a very interesting study, and... it will open the door to more research being done in malebreast cancer." The study may also raise awareness that men can indeed developbreast cancer, Boolbol said. Men should be aware of potential symptoms of breast cancer, theAmerican Cancer Society suggests. Among them: a lump or swelling,dimpling or puckering, a turning inward of the nipple, scaling ofthe nipple or breast skin, redness of the nipple or skin of thebreast, and nipple discharge.

Findings presented at medical meetings are typically consideredpreliminary until published in a peer-reviewed journal. More information To learn more about breast cancer in men, visit the American Cancer Society . SOURCES: May 4, 2012, news conference with: Jon Greif, D.O.,general surgeon, San Francisco; Susan K. Boolbol, M.D., chief,division of breast surgery, Beth Israel Medical Center, New YorkCity; May 4, 2012, presentation, American Society of BreastSurgeons annual meeting, Phoenix Copyright 息 2012 HealthDay . All rights reserved.